ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (66)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoeper, M.M.
Right arrow Articles by Niedermeyer, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoeper, M.M.
Right arrow Articles by Niedermeyer, J.
Eur Respir J 2004; 24:1007-1010
Copyright ©ERS Journals Ltd 2004

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

M.M. Hoeper1, C. Faulenbach1, H. Golpon1, J. Winkler2, T. Welte1 and J. Niedermeyer1

1 Dept of Respiratory Medicine, Hannover Medical School, Hannover, and 2 Dept of Cardiopulmonary Medicine, University of Leipzig, Leipzig, Germany

CORRESPONDENCE: M.M. Hoeper, Hannover Medical School, Dept of Respiratory Medicine, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Fax: 49 5115328536. E-mail: hoeper.marius@mh-hannover.de

Keywords: Bosentan, endothelin receptor antagonists, hypertension, phosphodiesterase inhibitors, pulmonary, sildenafil

Received: April 29, 2004
Accepted July 7, 2004


   Abstract
TOP
 Abstract
Patients and methods
 Results
 Discussion
 References
 
It has been proposed that targeted treatments should be combined for patients with idiopathic pulmonary arterial hypertension (IPAH) responding insufficiently to monotherapy.

This study followed the clinical course of nine patients with severe IPAH, in whom the endothelin receptor antagonist bosentan caused transient clinical improvement, eventually followed by a decline in exercise tolerance, who received adjunct treatment with the phospodiesterase-5-inhibitor sildenafil. Measurements included the 6-min walk distance (6MWD) and cardiopulmonary exercise testing (CPET).

The 6MWD at baseline was 346±66 m and improved to 403±80 m 3 months after introduction of bosentan treatment. However, this effect was not sustained and, after an interval of 11±5 months, the walk distance had declined to 277±80 m. At this point, sildenafil was added to bosentan. Three months later, the 6MWD had increased to 392±61 m and the patients remained stable throughout the median follow-up of 9 months (range 6–12). Measurement of the maximum oxygen uptake during CPET confirmed these results. The combination of bosentan and sildenafil was well tolerated by all patients.

These preliminary data suggest that combining bosentan and sildenafil may be safe and effective in patients with idiopathic pulmonary arterial hypertension.

Idiopathic pulmonary arterial hypertension (IPAH), formerly called primary pulmonary hypertension (PPH), is a disease of unknown aetiology, characterised by progressive pulmonary vascular remodelling, ultimately leading to right heart failure and death 1. Without targeted treatment, IPAH carries a grave prognosis, with a median survival of 2.8 yrs after diagnosis 3.

In the last few years, a number of novel treatments for this devastating disease have been developed and are now in use. Intravenous epoprostenol has been shown in several studies to improve haemodynamics, exercise tolerance and survival 4–6. To circumvent the risks, inconveniences and costs associated with continuous intravenous epoprostenol, stable prostacyclin analogues have been introduced that can be administered orally, subcutaneously or by inhalation 7. In patients with IPAH, all these substances have been shown to improve exercise tolerance and haemodynamics in relatively short-term clinical studies 8–10, but the effects on long-term survival have not been thoroughly investigated.

Besides prostaglandins, novel substances with different mechanisms of action have been introduced in recent years. The dual endothelin receptor antagonist bosentan has been approved throughout the western world for treatment of pulmonary arterial hypertension (PAH) 11. In addition, several case series and one small controlled study have suggested that phosphodiesterase-5-inhibitors, such as sildenafil, may have beneficial effects in PAH 12.

Despite the fact that all of these substances have positive effects in IPAH, they do not provide a cure and, in many patients, the disease will eventually progress. The optimal management for patients who exhibit clinical deterioration despite targeted treatment is unclear. The introduction of intravenous epoprostenol is an option for patients in whom treatment with endothelin receptor antagonists, nonintravenous prostanoids or sildenafil fails. Another option is combination treatment 14. A few uncontrolled clinical studies have suggested that combinations of aerosolised iloprost and sildenafil, as well as aerosolised iloprost and bosentan, are safe and effective in selected patients with progressive disease despite prostanoid treatment 15. Combining bosentan and sildenafil may also be an attractive choice, since both substances are orally available, act via different mechanisms and are usually well tolerated. This paper describes the clinical course of nine patients with severe and progressive IPAH who were treated with a combination of bosentan and sildenafil.


   Patients and methods
TOP
 Abstract
 Patients and methods
Results
 Discussion
 References
 
Between January 2002 and December 2003, 58 patients received bosentan for treatment of IPAH at Hannover Medical School (Hannover, Germany). Bosentan was used either as first-line therapy or in addition to a prostanoid (i.e. inhaled iloprost, oral beraprost or intravenous iloprost). Treatment efficacy was monitored primarily by the 6-min walk distance (6MWD) and cardiopulmonary exercise testing(CPET), and was targeted to reach pre-defined goals based on prognostically relevant variables: a 6MWD >380 m 6 and a peak oxygen uptake measured during CPET >10.4 mL·min–1·kg–1 17. Patients who did not reach these goals on two consecutive visits were offered additional treatment with sildenafil. There was no formal study protocol. All patients were informed about the fact that this approach was investigational, that long-term data on safety and efficacy of sildenafil in PAH were not available, that there were no experiences with the combination of bosentan and sildenafil, and about the alternative option to receive intravenous prostacyclin treatment.

Treatments and follow-up
All patients had an extensive diagnostic work-up to define the aetiology of pulmonary hypertension, including, but not limited to, ventilation-perfusion scanning, computed tomography of the chest, right heart catheterisation and pulmonary angiography, when indicated. Bosentan was considered first-line treatment for patients newly diagnosed with IPAH. After initiation of bosentan treatment, the patients were seen in the outpatient clinic in 3–4 monthly intervals. Follow-up examinations included regular 6MWD 18 and CPET 16. Repeated right heart catheterisations were not part of the routine follow-up programme.

Bosentan treatment was started at a dose of 2x62.5 mg andthe dose was increased to 2x125 mg after 4 weeks in allpatients. Liver enzymes were monitored every 4 weeks. Thedose of bosentan was not changed throughout the observation period.

Sildenafil was started at a dose of 3x25 mg (or 4x25 mg) and was increased after 4–12 weeks to 3x50 mg when the response to the initial dose was not sufficient (i.e. when the treatment goals as defined above where not reached).

Analysis
All values are given as mean±SD. Two baselines were set: the first one before bosentan was started and the second one before sildenafil was started. The treatment effects after 3 months were compared with the baseline values using pairedt-tests (two-sided). A p-value <0.05 was considered statistically significant.


   Results
TOP
 Abstract
 Patients and methods
 Results
Discussion
 References
 
Within the observation period, 2002–2003, nine out of 58 patients with IPAH, initially treated with bosentan or a combination of bosentan and a prostanoid, fulfilled the predefined criteria of clinical worsening as defined above. These patients suffered from severe and progressive pulmonary hypertension, and were in New York Heart Association (NYHA) functional class III or IV before treatment was started. All patients were nonresponders to acute vasodilator challenge. The baseline characteristics and haemodynamics of these patients are shown in table 1Go.


View this table:
[in this window]
[in a new window]
  		Table 1— Patients' baseline characteristics and haemodynamics

 
Functional classification
At baseline, eight patients were functional class (FC) III and one patient was FC IV. Three months after bosentan was started, two patients had improved to FC II and the patient who formerly was FC IV had improved to FC III. However, after a follow-up of 11±5 months, deterioration occurred in all patients and, before sildenafil was added to bosentan, seven patients were FC III and two patients were FC IV. After 3 months of treatment with bosentan and sildenafil, six patients were FC III and three patients were FC II. During the follow-up period of 6–12 months, two further patients improved from FC III to FC II (table 2Go).


View this table:
[in this window]
[in a new window]
  		Table 2— Individual functional classes (New York Heart Association (NYHA)) and 6-min walk distance (6-MWD)

 
Six-min walk distance
As shown in figure 1Go and table 2Go, the 6MWD at baseline was 346±66 m. After introduction of bosentan treatment, the 6MWD improved by 57 m to 403±80 m (p=0.0003). However, this effect was not sustained and, after an interval of 11±5 months, the walk distance had declined to 277±80 m. At this point, sildenafil was added to bosentan. Three months later, the 6MWD had increased to 392±61 m (p=0.007) and the patients remained stable throughout the median follow-up of 9 months (range 6–12).



View larger version (12K):
[in this window]
[in a new window]
  		Fig. 1.— Six-min walk distance (6MWD) of nine patients with idiopathic pulmonary arterial hypertension at baseline 1 (before treatment with bosentan), 3 months after introduction of bosentan, baseline 2 (11±5 months later before addition of sildenafil), 3 months later and 6–12 months later. Open arrow: bosentan started; closed arrow sildenafil started.

 
Cardiopulmonary exercise testing
Complete sets of data from CPET at all time points (baseline 1, three months after introduction of bosentan, baseline 2 and 3 months after the addition of sildenafil) were available from six patients. In these patients, the peak oxygen uptake (V'O2,peak) was 9.9±1.9 mL·min–1·kg–1 at baseline and increased to 12.3±1.9 mL·min–1·kg–1 3 months after introduction of bosentan (p=0.02). As with the walking distance, this effect was not sustained and, before introduction of sildenafil, V'O2,peak had decreased to 10.4±2.3 mL·min–1·kg–1. Three months after sildenafil was added to bosentan, V'O2,peak had increased to 13.8±1.5 mL·min–1·kg–1 (p=0.006).

Side-effects
None of the patients in this case series died or experienced any drug-related serious adverse event. There were no abnormalities of liver enzymes before or after the introduction of bosentan, or after addition of sildenafil. All patients reported minor headache and flushing when sildenafil was added to bosentan, but these problems resolved within a few days without dose adjustments. The same was true with heartburn, reported by one patient after sildenafil was started. No patient described symptoms attributable to hypotension and there were no episodes of syncope during the observation period.


   Discussion
TOP
 Abstract
 Patients and methods
 Results
 Discussion
References
 
This case series may serve as a pilot trial showing that combining bosentan and sildenafil might be feasible in patients with IPAH. This combination was well tolerated by all patients and proved to be highly efficient. Of note, this patient population consisted of a "negatively" selected subgroup of young patients with very severe and rapidly progressive IPAH. Before targeted treatment was initiated, allpatients were in functional class NYHA III or IV, and haemodynamic assessment confirmed the presence of advanced pulmonary hypertension with a mean pulmonary artery pressure of 62±12 mmHg, a cardiac index of 1.6±0.3 L·min–1·m–2 and a pulmonary vascular resistance of 1,549±440 dynes·s·cm–5. In accordance with current recommendations 7, bosentan was started as first-line treatment, resulting in clinical improvement and increased exercise tolerance as determined by 6MWD and CPET. However, in contrast to the majority of patients receiving treatment with bosentan, this effect was not sustained. After an average period of close to 1 yr, the patients showed clinical deterioration and a marked decline in 6MWD, as well as in V'O2,peak. It is the unfortunate clinical reality that, even with the novel targeted treatments available for PAH, a certain proportion of patients are going to deteriorate after initial improvement. Those patients are very likely to die from their underlying disease and they do require aggressive treatment. The most recent world conference on pulmonary hypertension recommended that prostacyclin treatment or, alternatively, combination treatment should be initiated in patients not responding sufficiently to treatment with endothelin receptor antagonists or nonintravenous prostanoids 14. Since bosentan clearly had a beneficial effect in all of the patients in the current study, the authors decided to initiate combination treatment, reserving intravenous prostacyclin for treatment failures. For reasons discussed below, sildenafil was chosen as an add-on treatment. The combination of bosentan and sildenafil was surprisingly well tolerated by all patients and resulted in marked clinical improvement. The pre-defined treatment goals (6MWD >380 m and V'O2,peak >10.4 mL·min–1·kg–1) were reached in six out of nine patients. The remaining patients were judged as sufficiently stable and showed a tendency towards further improvement during follow-up, so that introduction of intravenous prostacyclin was not deemed immediately necessary. It is noteworthy that none of the patients died during the observation period of 21±3 months, even though the expected 1-yr and 2-yr survival probabilities of these patients based on their baseline haemodynamics according to the formula of the National Institutes of Health were 0.64 and 0.51, respectively 3.

Obviously, this observational report has several inherent limitations: there was no control group, the patient population was small and the overall observation time was rather limited. In addition, treatment with bosentan and sildenafil was not part of a formal study protocol, and serial right heart catheter examinations were not performed and, therefore, haemodynamic follow-up data were not available. Although these data would be of value, it is the authors' practice to base most therapeutic decisions on the results of patient's self reporting (functional classification), clinical examination, 6MWT and CPET, and to reserve right heart catheterisation for open questions or for certain therapeutic decisions, such as listing for highly urgent lung transplantation.

Bosentan and sildenafil were combined rather than bosentan and a prostanoid for several reasons: at the time when combination treatment was initiated in the patients, bosentan was the only drug approved for treatment of IPAH in Germany (sildenafil, beraprost and treprostinil have not been approved in Germany, and aerosolised iloprost was officially introduced in January 2004); beraprost or treprostinil were not considered as first choices for combination treatment because the former drug has not been shown to exhibit long-term clinical efficacy 19 and the latter one commonly causes substantial infusion site pain 10; compared to inhaled iloprost, sildenafil has the practical advantage of being orally administered rather than requiring six to nine inhalations daily; and in addition, although it has been shown that inhaled iloprost and sildenafil have synergistic effects 15, it was hypothesised that the combination of substances with different intracellular modes of action might be advantageous in the long run, although comparative studies are required to resolve this issue.

Economical considerations also contributed to the decision to combine bosentan and sildenafil. In Germany, the annual treatment costs for a single patient are ~45,000 for bosentan, 70,000 for inhaled iloprost and 5,000–10,000 (depending on the dose) for sildenafil. Thus, the annual costs for combining bosentan and sildenafil are 50,000–55,000, compared to 75,000–80,000 for inhaled iloprost plus sildenafil and 115,000 for inhaled iloprost plus bosentan. In comparison, in Germany, the annual treatment costs for intravenous epoprostenol are 230,000 (at a dose of 25 ng·kg–1·min–1, which is a typical average dose in patients receiving epoprostenol for >1 yr 5) and those for intravenous iloprost are 180,000 (at a dose of 2 ng·kg–1·min–1, a typical average dose for intravenous iloprost 16). Thus, when the clinical situation mandates combination treatment or the introduction of intravenous prostacyclin, the annual savings with the combination bosentan and sildenafil are >100,000 for every patient, meaning that the approach in this study resulted in savings of>1,000,000 just based on the nine patients described.

Despite these considerations, many open questions remain: it is unknown whether combination treatment is truly more efficient than single treatment (although theoretical reasoning clearly favours combination treatment, switching to sildenafil may have been equally effective as combining bosentan and sildenafil); it is unknown which combination regimens exert favourable long-term results (this will be difficult to answer as the number of potentially useful combinations is exponentially increasing with the introduction of novel treatments for PAH); and finally, so far, the combination of bosentan and sildenafil has only been used in patients with IPAH, and it is unknown whether these observations also apply to other forms of pulmonary hypertension.

In conclusion, the data presented here provide preliminary evidence that the combination of bosentan and sildenafil may be safe and effective in selected patients with idiopathic pulmonary arterial hypertension.


   References
TOP
 Abstract
 Patients and methods
 Results
 Discussion
 References
 

  1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111–117.[Free Full Text]
  2. Gaine S. Pulmonary hypertension. JAMA 2000;284:3160–3168.[Abstract/Free Full Text]
  3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–349.
  4. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296–302.[Abstract/Free Full Text]
  5. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477–1482.[Abstract/Free Full Text]
  6. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Prognostic factors and survival. J Am Coll Cardiol 2002;40:780–788.[Abstract/Free Full Text]
  7. Hoeper MM, Galie N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1209–1216.[Free Full Text]
  8. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496–1502.[Abstract/Free Full Text]
  9. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–329.[Abstract/Free Full Text]
  10. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800–804.[Abstract/Free Full Text]
  11. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.[Abstract/Free Full Text]
  12. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;20:20.
  13. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149–1153.[Abstract/Free Full Text]
  14. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:S81–S88.
  15. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158–164.[Abstract/Free Full Text]
  16. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003;22:330–334.[Abstract/Free Full Text]
  17. Wensel R, Opitz C, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106:319–324.[Abstract/Free Full Text]
  18. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–117.[Free Full Text]
  19. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119–2125.[Abstract/Free Full Text]
  20. Wilkens H, Guth A, Koenig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218–1222.[Abstract/Free Full Text]
  21. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515–522.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
G. Simonneau, L. J. Rubin, N. Galie, R. J. Barst, T. R. Fleming, A. E. Frost, P. J. Engel, M. R. Kramer, G. Burgess, L. Collings, et al.
Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial
Ann Intern Med, October 21, 2008; 149(8): 521 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Respiratory DiseaseHome page
K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert
Review: Therapeutic advances in pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
Eur. Respir. J., July 1, 2008; 32(1): 198 - 209.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. E. Wrishko, J. Dingemanse, A. Yu, C. Darstein, D. L. Phillips, and M. I. Mitchell
Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects
J. Clin. Pharmacol., May 1, 2008; 48(5): 610 - 618.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Heart, March 1, 2008; 94(Suppl_1): i1 - i41.
[Full Text] [PDF]

Home page
 ThoraxHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Dupuis and M. M. Hoeper
Endothelin receptor antagonists in pulmonary arterial hypertension
Eur. Respir. J., February 1, 2008; 31(2): 407 - 415.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. Takaoka, J. L. Faul, and R. Doyle
Current Therapies for Pulmonary Arterial Hypertension
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 137 - 148.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
M. M. Hoeper
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value
Eur. Respir. J., March 1, 2007; 29(3): 432 - 434.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
S. C. Mathai, R. E. Girgis, M. R. Fisher, H. C. Champion, T. Housten-Harris, A. Zaiman, and P. M. Hassoun
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
Eur. Respir. J., March 1, 2007; 29(3): 469 - 475.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos
Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study
Heart, March 1, 2007; 93(3): 350 - 354.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S A van Wolferen, A Boonstra, J T Marcus, K M J Marques, J G F Bronzwaer, P E Postmus, and A Vonk-Noordegraaf
Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension
Heart, December 1, 2006; 92(12): 1860 - 1861.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. V. McLaughlin, R. J. Oudiz, A. Frost, V. F. Tapson, S. Murali, R. N. Channick, D. B. Badesch, R. J. Barst, H. H. Hsu, and L. J. Rubin
Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1257 - 1263.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Mereles, N. Ehlken, S. Kreuscher, S. Ghofrani, M. M. Hoeper, M. Halank, F. J. Meyer, G. Karger, J. Buss, J. Juenger, et al.
Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension
Circulation, October 3, 2006; 114(14): 1482 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. M. Hoeper, H. Leuchte, M. Halank, H. Wilkens, F. J. Meyer, H. J. Seyfarth, R. Wensel, F. Ripken, H. Bremer, S. Kluge, et al.
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Eur. Respir. J., October 1, 2006; 28(4): 691 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies
Cardiovasc Res, October 1, 2006; 72(1): 30 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
M. Clozel, P. Hess, M. Rey, M. Iglarz, C. Binkert, and C. Qiu
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Experimental Biology and Medicine, June 1, 2006; 231(6): 967 - 973.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. M. Hoeper and L. J. Rubin
Update in pulmonary hypertension 2005.
Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 499 - 505.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, and J. Niedermeyer
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Eur. Respir. J., November 1, 2005; 26(5): 858 - 863.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. M. Hoeper, T. Kramm, H. Wilkens, C. Schulze, H. J. Schafers, T. Welte, and E. Mayer
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chest, October 1, 2005; 128(4): 2363 - 2367.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. H. Morice, S. Mulrennan, and A. Clark
Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension
Eur. Respir. J., July 1, 2005; 26(1): 180 - 180.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. V. McLaughin and M. M. Hoeper
Pulmonary Arterial Hypertension: The Race for the Most Effective Treatment
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1199 - 1201.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. R. Wilkins, G. A. Paul, J. W. Strange, N. Tunariu, W. Gin-Sing, W. A. Banya, M. A. Westwood, A. Stefanidis, L. L. Ng, D. J. Pennell, et al.
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1292 - 1297.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (66)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoeper, M.M.
Right arrow Articles by Niedermeyer, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoeper, M.M.
Right arrow Articles by Niedermeyer, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS